Zobrazeno 1 - 10
of 803
pro vyhledávání: '"Christopher R Flowers"'
Publikováno v:
Pharmacoepidemiology, Vol 3, Iss 3, Pp 252-264 (2024)
The future directions in leveraging real-world evidence (RWE) and real-world data (RWD) in the field of lymphoma, as compared to traditional experimental clinical trials, are poised to significantly impact research methodologies, treatment strategies
Externí odkaz:
https://doaj.org/article/d0b5d43e40cd4e559035c477f665558d
Autor:
Rong Deng, Leonid Gibiansky, Tong Lu, Christopher R. Flowers, Laurie H. Sehn, Qi Liu, Priya Agarwal, Michael Z. Liao, Randall Dere, Calvin Lee, Gabriel Man, Jamie Hirata, Chunze Li, Dale Miles
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 6, Pp 1055-1066 (2024)
Abstract Polatuzumab vedotin is a CD79b‐directed antibody–drug conjugate that targets B cells and delivers the cytotoxic payload monomethyl auristatin E (MMAE). The phase III POLARIX study (NCT03274492) evaluated polatuzumab vedotin in combinatio
Externí odkaz:
https://doaj.org/article/94a1657630df4f2992ff53a1a61eb869
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Single-cell RNA sequencing (scRNA-seq) technology has been widely used to study the differences in gene expression at the single cell level, providing insights into the research of cell development, differentiation, and functional heterogene
Externí odkaz:
https://doaj.org/article/41fd27dd21554bddb14a9c1ba9e30400
Autor:
Meixian Huang, Zeng Ke, Mi-Ae Lyu, Lucia Masarova, Tara Sadeghi, Christopher R. Flowers, Simrit Parmar
Publikováno v:
iScience, Vol 27, Iss 9, Pp 110830- (2024)
Summary: CXCR4 cell surface expression is critical for the homing of T regulatory (Treg) cells to the bone marrow (BM). We hypothesize that CXCR4 enrichment on Tregs cell surface may abbreviate their transit time to reach BM. Umbilical cord-blood CD2
Externí odkaz:
https://doaj.org/article/33d674a18d9d471dbea146cf07d4d88c
Autor:
Ashwath Gurumurthi, Collin K. Chin, Lei Feng, Nathan H. Fowler, Paolo Strati, Fredrick B. Hagemeister, Luis E. Fayad, Jason R. Westin, Chizobam Obi, Janine Arafat, Ranjit Nair, Raphael E. Steiner, Sattva S. Neelapu, Christopher R. Flowers, Loretta J. Nastoupil
Publikováno v:
EClinicalMedicine, Vol 74, Iss , Pp 102747- (2024)
Summary: Background: Rituximab and lenalidomide is a preferred option for relapsed indolent B cell non-Hodgkin lymphoma. Obinutuzumab may be a superior combination partner with lenalidomide given enhanced antibody dependent cellular cytotoxicity and
Externí odkaz:
https://doaj.org/article/ce025c6f41e44776b07e12e8ef403353
Autor:
Julie M. Vose, Kai Fu, Lu Wang, Adnan Mansoor, Douglas Stewart, Hongxia Cheng, Lynette Smith, Ji Yuan, Hina Naushad Qureishi, Brian K. Link, Melissa H. Cessna, Paul M. Barr, Brad S. Kahl, Matthew S. Mckinney, Nadia Khan, Ranjana H. Advani, Peter Martin, Andre H. Goy, Tycel J. Phillips, Amitkumar Mehta, Manali Kamdar, Michael Crump, Barbara Pro, Christopher R. Flowers, Caron A. Jacobson, Sonali M. Smith, Deborah M. Stephens, Veronika Bachanova, Zhaohui Jin, Shishou Wu, Francisco Hernandez-Ilizaliturri, Pallawi Torka, Andrea Anampa-Guzmán, Farshid Kashef, Xing Li, Sunandini Sharma, Timothy C. Greiner, James O. Armitage, Matthew Lunning, Dennis D. Weisenburger, Robert G. Bociek, Javeed Iqbal, Guohua Yu, Chengfeng Bi, the North American Mantle Cell Lymphoma Consortium
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-12 (2023)
Abstract Background Patients with mantle cell lymphoma (MCL) exhibit a wide variation in clinical presentation and outcome. However, the commonly used prognostic models are outdated and inadequate to address the needs of the current multidisciplinary
Externí odkaz:
https://doaj.org/article/38f17dfbe7af46e394e36a8885eeec63
Autor:
Preetesh Jain, Krystle Nomie, Nikita Kotlov, VitaIy Segodin, Holly Hill, Chi Young Ok, Ahmed Fetooh, Rashmi Kanagal-Shamanna, Francisco Vega, Alexander Bagaev, Nathan Fowler, Christopher R. Flowers, Michael Wang
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-5 (2023)
Externí odkaz:
https://doaj.org/article/19cd5314563442188352426c12d4f839
Autor:
Andrew P. Jallouk, Naishu Kui, Ryan Sun, Jason R. Westin, Raphael E. Steiner, Ranjit Nair, Loretta J. Nastoupil, Luis E. Fayad, Ajlan Al Zaki, Misha Hawkins, Sherry Adkins, Mansoor Noorani, Kaberi Das, Jared Henderson, Elizabeth J. Shpall, Partow Kebriaei, Jeremy Ramdial, Christopher R. Flowers, Sattva S. Neelapu, Sairah Ahmed, Paolo Strati
Publikováno v:
Haematologica, Vol 109, Iss 5 (2023)
Complications occurring after lymphodepleting chemotherapy (LDC) may delay chimeric antigen receptor (CAR) T-cell infusion. The effect of these delays on clinical outcomes is unclear. We performed a retrospective analysis of 240 patients with relapse
Externí odkaz:
https://doaj.org/article/b01259b6f4fa46b6872193b9823dd88d
Autor:
Matthew J. Maurer, Carla Casulo, Melissa C. Larson, Thomas M. Habermann, Izidore S. Lossos, Yucai Wang, Loretta J. Nastoupil, Christopher Strouse, Dai Chihara, Peter Martin, Jonathon B. Cohen, Brad S. Kahl, W Richard Burack, Jean L. Koff, Yong Mun, Anthony Masaquel, Mei Wu, Michael C. Wei, Ashwini Shewade, Jia Li, James R. Cerhan, Brian K. Link, Christopher R. Flowers
Publikováno v:
Haematologica, Vol 999, Iss 1 (2023)
Mosunetuzumab is a novel bispecific antibody targeting epitopes on CD3 on T cells and CD20 on B cells with the goal of inducing T-cell mediated elimination of malignant B cells. A recent pivotal phase I/II clinical trial (GO29781) demonstrated that m
Externí odkaz:
https://doaj.org/article/1d7e46afb331468e9c6f00cad9ff0929
Autor:
Raphael E. Steiner, Edwin R. Parra, Francisco Vega, Lei Feng, Jason R. Westin, Sattva S. Neelapu, Paolo Strati, Michael R. Green, Christopher R. Flowers, Luisa M. Solis, Ignacio I. Wistuba, Sairah Ahmed, Ranjit Nair, Fredrick B. Hagemeister, Mansoor Noorani, Mario L. Marques-Piubelli
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-5 (2023)
Abstract Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a rare, aggressive subtype of non-Hodgkin lymphoma and has a complex inflammatory microenvironment. Although most patients can be cured with standard-of-care immunochemotherapy, p
Externí odkaz:
https://doaj.org/article/e3114eba62f94495bc871889c61eb0f9